Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403533 · ClinicalTrials.gov registry record · Phase 2
Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00403533: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00403533 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00403533, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
We hypothesize that atorvastatin will decrease HCV viral load in patients taking the medication. Cholesterol is needed for HCV virion production. Cell culture studies have shown that atorvastatin (an HMG-CoA reductase inhibitor) decreases HCV viral replication. As atorvastatin has been proven to decrease heart attack and stroke in patients with high cholesterol, this medication is indicated for the treatment of elevated cholesterol in at risk individuals. Therefore we propose to study the effect atorvastatin has on the viral load of patients initiated on atorvastatin therapy for their elevated cholesterol.
Interventions
- DRUG 20 mg of atorvastatin daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403533
The ClinicalTrials.gov registry entry for NCT00403533 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 20 mg of atorvastatin daily is the first listed.
NCT00403533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00403533 about?
NCT00403533 is a clinical study titled "Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus". We hypothesize that atorvastatin will decrease HCV viral load in patients taking the medication. Cholesterol is needed for HCV virion production. Cell culture studies have shown that atorvastatin (an HMG-CoA reductase inhibitor) decreases HCV viral replication. As atorvastatin has been proven to de...
What is the current status of trial NCT00403533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2006-02. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00403533?
The interventions under investigation include: 20 mg of atorvastatin daily (DRUG).
Who is sponsoring clinical trial NCT00403533?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.